PD
NGNE icon

Point72 (DIFC)’s Neurogene NGNE Stock Holding History

Point72 (DIFC)’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$14.5K Buy
+835
New +$16.8K ﹤0.01% 904

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 (DIFC)'s NGNE Position: Q3 2025 in Review

Point72 (DIFC) opened a new position in Neurogene (NGNE) in Q3 2025: 835 shares worth $14.5K. The stake represents ﹤0.01% of the portfolio and ranks #904 among its holdings.

88 funds tracked by Wall St. Rank hold NGNE as of Q3 2025.

  • Point72 (DIFC) held 835 shares of Neurogene worth $14.5K as of Q3 2025.
  • Neurogene was a new Point72 (DIFC) position in Q3 2025.
  • Neurogene made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #904 holding.
  • 88 funds tracked by Wall St. Rank held Neurogene as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.